ORPHA:319244
Chapare hemorrhagic fever
Publications
27
40.6th percentile
Trials
0
Interventional, condition-specific
Researchers
198
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Chapare hemorrhagic fever, caused by the Chapare virus (a new arenavirus), discovered from a small outbreak in Cochabamba, Bolivia between 2003 and 2004, is an acute viral hemorrhagic fever characterized by fever, myalgia, arthralgia, and multiple hemorrhagic signs. About a third of untreated cases go on to develop more severe symptoms with delirium, coma and convulsions and death (in one case). No other cases have been reported since.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017878
- UMLS:C4274434
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
27 matched papers (25 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 62 for broader category hemorrhagic fever
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
27
27 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
27 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
25 in the last 10 years · high confidence · 40.6th percentile (publications denominator)
Phrase hits: 27 · MeSH hits: 0
Who's working on it?
198
Distinct author names in 27 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Paessler S3 papers · 2024
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Papers in Europe PMC - 02Brignone J2 papers · 2024
Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui, Monteagudo 2510, Pergamino 2700, Argentina.
Papers in Europe PMC - 03Cross RW2 papers · 2025
Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610, USA.
Papers in Europe PMC - 04Edhi S2 papers · 2025
Andhra University College of Pharmaceutical Sciences, Visakhapatnam 530003, Andhra Pradesh, India.
Papers in Europe PMC - 05Geisbert TW2 papers · 2025
Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555-0610, USA.
Papers in Europe PMC - 06Huang C2 papers · 2024
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Papers in Europe PMC - 07Karanam SK2 papers · 2025
Department of Pharmaceutical Biotechnology, Maharajah's College of Pharmacy, Vizianagaram 535002, Andhra Pradesh, India.
Papers in Europe PMC - 08Klena JD2 papers · 2024
Viral Special Pathogens Branch, The Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30329, USA.
Papers in Europe PMC - 09Littlefield K2 papers · 2024
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Papers in Europe PMC - 10Maruyama J2 papers · 2024
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 62 trials are registered for hemorrhagic fever, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
62 interventional trials matched hemorrhagic fever, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hemorrhagic fever
62
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07543458·NOT YET RECRUITING·Therapeutics for Moderate and Severe Dengue
Conditions: Dengue · Severe Dengue · Mosquito-Borne Diseases · Vector Borne Diseases·Matched via name phrase
- NCT06860334·NOT YET RECRUITING·UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF
Conditions: Crimean-Congo Hemorrhagic Fever·Matched via name phrase
- NCT06799013·RECRUITING·Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Conditions: Vaccine · Crimean-Congo Hemorrhagic Fever·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Chapare hemorrhagic fever"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chapare hemorrhagic fever"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hemorrhagic fever"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:20:30.496Z